Profile data is unavailable for this security.
About the company
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
- Revenue in HKD (TTM)9.24bn
- Net income in HKD1.82bn
- Incorporated2006
- Employees5.61k
- Location3SBio IncNo. 3 A1, Road 10Shenyang Economy & TechnologyDevelopment ZoneSHENYANG 110027ChinaCHN
- Phone+86 2 425811820
- Fax+86 2 425811821
- Websitehttps://www.3sbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Everest Medicines Ltd | 459.39m | -1.16bn | 8.28bn | 520.00 | -- | 1.69 | -- | 18.02 | -3.59 | -3.59 | 1.42 | 15.09 | 0.0756 | 5.23 | 3.22 | 1,063,409.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Cansino Biologics Inc | 668.99m | -951.24m | 10.69bn | 1.49k | -- | 1.16 | -- | 15.97 | -3.85 | -3.85 | 2.71 | 22.48 | 0.0676 | 1.28 | 0.8385 | 447,782.40 | -10.15 | -4.27 | -13.73 | -5.60 | 14.38 | -- | -150.19 | -27.72 | 2.19 | -- | 0.3028 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Luye Pharma Group Ltd | 6.93bn | 845.64m | 12.30bn | 5.23k | 14.55 | 0.8608 | 7.23 | 1.78 | 0.2248 | 0.2248 | 1.84 | 3.80 | 0.236 | 2.44 | 3.02 | 1,314,909.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Shanghai Henlius Biotech Inc | 6.19bn | 759.89m | 12.36bn | 3.55k | 16.31 | 4.37 | 10.61 | 2.00 | 1.39 | 1.39 | 11.34 | 5.21 | 0.5764 | 1.90 | 6.82 | 1,702,200.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 12.42bn | 5.80k | 9.14 | 1.72 | 6.79 | 1.92 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| 3SBio Inc | 9.24bn | 1.82bn | 16.31bn | 5.61k | 9.11 | 1.03 | 7.22 | 1.76 | 0.7473 | 0.7473 | 3.79 | 6.59 | 0.3575 | 1.52 | 6.87 | 1,708,233.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Simcere Pharmaceutical Group Ltd | 6.96bn | -1.21bn | 16.68bn | 6.41k | -- | 2.21 | -- | 2.40 | -0.4626 | -0.4626 | 2.70 | 2.98 | 0.5198 | 2.19 | 2.64 | 990,578.20 | -9.04 | 10.17 | -11.71 | 15.60 | 77.02 | 78.82 | -17.40 | 17.50 | 1.88 | 0.4721 | 0.1461 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 17.82bn | 10.78k | 7.29 | 1.13 | 6.20 | 1.68 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
| Zai Lab Ltd | 2.51bn | -2.32bn | 18.99bn | 2.18k | -- | 3.42 | -- | 7.57 | -2.39 | -2.39 | 2.58 | 5.58 | 0.3083 | 3.04 | 5.52 | -- | -28.50 | -37.72 | -34.92 | -42.72 | 63.17 | 64.75 | -92.44 | -282.44 | 3.29 | -- | 0.0908 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.38bn | 3.19bn | 19.91bn | 15.00k | 6.24 | 1.34 | 5.22 | 1.30 | 1.76 | 1.76 | 8.46 | 8.17 | 0.6578 | 3.30 | 5.67 | 1,025,069.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| China Traditional Chinese Med Hldg CoLtd | 18.88bn | 1.01bn | 22.11bn | 17.72k | 21.95 | 0.9425 | 9.63 | 1.17 | 0.20 | 0.20 | 3.75 | 4.66 | 0.453 | 1.54 | 1.82 | 1,091,315.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 7.39 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| China Medical System Holdings Ltd | 7.70bn | 1.53bn | 22.20bn | 5.78k | 14.57 | 1.26 | 12.55 | 2.88 | 0.6246 | 0.6246 | 3.15 | 7.23 | 0.384 | 2.89 | 5.65 | 1,350,396.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
Data as of Oct 10 2024. Currency figures normalised to 3SBio Inc's reporting currency: Hong Kong Dollar HKD
10.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 68.21m | 2.82% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 36.68m | 1.52% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 31.29m | 1.30% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 25.74m | 1.07% |
| Bankinter Gesti�n de Activos SA SGIICas of 31 Dec 2023 | 22.94m | 0.95% |
| BlackRock Fund Advisorsas of 27 Jun 2024 | 21.06m | 0.87% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 15.86m | 0.66% |
| BlackRock (Netherlands) BVas of 27 Jun 2024 | 10.72m | 0.44% |
| Ninety One Hong Kong Ltd.as of 30 Apr 2024 | 10.04m | 0.42% |
| BlackRock Investment Management (UK) Ltd.as of 27 Jun 2024 | 9.41m | 0.39% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
